Adaptimmune's IPO

Adaptimmune raised a round of funding on May 06, 2015. Investors include Public.

Adaptimmune is focused on the use of T cell therapy with engineered T cell receptors to treat cancer and infectious disease. Established in July 2008 with a research base in Oxford, UK and a clinical …

Articles about Adaptimmune's IPO: